These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 17505259)

  • 1. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
    Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
    Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
    Kuźbicki L; Sarnecka A; Chwirot BW
    Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.
    Kuzbicki L; Lange D; Chwirot BW
    Melanoma Res; 2009 Oct; 19(5):294-300. PubMed ID: 19543125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
    Kuźbicki L; Aładowicz E; Chwirot BW
    Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
    Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
    Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
    Kuźbicki L; Gajo B; Chwirot BW
    Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma.
    Menzies SW; Bischof L; Talbot H; Gutenev A; Avramidis M; Wong L; Lo SK; Mackellar G; Skladnev V; McCarthy W; Kelly J; Cranney B; Lye P; Rabinovitz H; Oliviero M; Blum A; Varol A; De'Ambrosis B; McCleod R; Koga H; Grin C; Braun R; Johr R
    Arch Dermatol; 2005 Nov; 141(11):1388-96. PubMed ID: 16301386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions.
    Blum A; Luedtke H; Ellwanger U; Schwabe R; Rassner G; Garbe C
    Br J Dermatol; 2004 Nov; 151(5):1029-38. PubMed ID: 15541081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic applications of the marker.
    Sztramska A; Dymerska D; Chwirot BW
    Melanoma Res; 2008 Aug; 18(4):259-67. PubMed ID: 18626310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the ets-1 proto-oncogene in melanocytic lesions.
    Keehn CA; Smoller BR; Morgan MB
    Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
    Pires I; Garcia A; Prada J; Queiroga FL
    J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions.
    Minami S; Lum CA; Kitagawa KM; Namiki TS
    Int J Dermatol; 2011 Jan; 50(1):24-9. PubMed ID: 21182498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan.
    Saida T; Miyazaki A; Oguchi S; Ishihara Y; Yamazaki Y; Murase S; Yoshikawa S; Tsuchida T; Kawabata Y; Tamaki K
    Arch Dermatol; 2004 Oct; 140(10):1233-8. PubMed ID: 15492186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
    Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
    Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.